Spyre Therapeutics (SYRE) Research & Development (2016 - 2025)
Historic Research & Development for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $45.2 million.
- Spyre Therapeutics' Research & Development rose 112.42% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.5 million, marking a year-over-year increase of 2158.16%. This contributed to the annual value of $162.8 million for FY2024, which is 8188.01% up from last year.
- Spyre Therapeutics' Research & Development amounted to $45.2 million in Q3 2025, which was up 112.42% from $40.1 million recorded in Q2 2025.
- Spyre Therapeutics' Research & Development's 5-year high stood at $50.5 million during Q4 2024, with a 5-year trough of $11.9 million in Q1 2021.
- Its 5-year average for Research & Development is $26.1 million, with a median of $17.4 million in 2023.
- As far as peak fluctuations go, Spyre Therapeutics' Research & Development crashed by 1950.32% in 2021, and later surged by 15354.24% in 2024.
- Quarter analysis of 5 years shows Spyre Therapeutics' Research & Development stood at $16.8 million in 2021, then fell by 15.08% to $14.3 million in 2022, then soared by 136.35% to $33.7 million in 2023, then soared by 49.88% to $50.5 million in 2024, then dropped by 10.37% to $45.2 million in 2025.
- Its Research & Development was $45.2 million in Q3 2025, compared to $40.1 million in Q2 2025 and $41.6 million in Q1 2025.